Drugs / CHXCART01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06866873 | May 2024 → Dec 2037 expected | B-cell non-Hodgkin lymphoma, childhood acute lymphoblastic leukemia | Hong Kong Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHXCART01 | “CAR-T cell (CHXCART01) infusion intravenously once at a dose of 0.2-2 million cells/kg recipient body weight” NCT06866873 ↗ |
| Modality | Cell therapy | “autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR)” NCT06866873 ↗ |
| Route | Intravenous | “CAR-T cell (CHXCART01) infusion intravenously once at a dose of 0.2-2 million cells/kg recipient body weight” NCT06866873 ↗ |
| Target | CD19 | “a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19” NCT06866873 ↗ |